Navigation Links
Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
Date:6/22/2010

SAN FRANCISCO, June 22 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Gregory W. Schafer as senior vice president and chief financial officer.  Mr. Schafer will be responsible for the Company's finance, accounting, planning, investor relations and treasury functions.

"Greg's finance and operations experience in the life sciences industry make him an ideal fit for Jennerex at this pivotal time for the company," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "Importantly, Greg's successful track record in raising capital and his involvement in bringing products through clinical development to the market will make him invaluable as we move JX-594 into Phase 3 clinical trials.  Additionally, we are grateful to Ian Malone, who has been a significant contributor to Jennerex as our CFO in recent years and who has now transitioned into an advisory capacity."

Mr. Schafer brings more than 20 years of broad functional and strategic leadership expertise to Jennerex and has raised over $600 million in public and private transactions to fund biotechnology product development and commercialization activities.  Most recently, he served as chief financial officer of Onyx Pharmaceuticals, Inc., where he was responsible for finance, accounting, risk management, and strategic and operational planning.  Prior to Onyx, he served as chief financial officer and vice president of finance for Cerus Corporation, where he played a key role in transitioning the company from early-stage development to a commercial enterprise with an approved product.  Prior to Cerus, Mr. Schafer worked as a management consultant for Deloitte and Touche, LLP and as an engineer specializing in biologics manufacturing.  Mr. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company.  He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer — an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Busan, South Korea.  For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Announces Presentations at Upcoming Conferences
2. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
3. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
4. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
8. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
9. EPEMED, the European Personalised Medicine Association, Appoints Executive Director
10. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
11. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)...  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is teaming up with Auto ... to lower diabetes healthcare costs in Canada ... is available throughout all provinces and territories in ... for additional savings when shopping for Dario supplies in ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... , May 3, 2017  West Pharmaceutical ... innovative solutions for injectable drug administration, announced today ... Affairs and Technical Services, and Diane Paskiet ... and offering presentations focused on West,s expertise in ... products, as well as providing commentary on updated ...
Breaking Medicine Technology:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... availability of video chat as a standard feature on its secure clinical communication ... text to voice to video depending on the type and urgency of a ...
(Date:5/23/2017)... ... ... New patients with symptoms of gum disease in San Diego, ... treatments from the doctors at Art of Dentistry, without first receiving a referral. Drs. ... of receiving qualified treatment in order to avoid systemic health effects associated with untreated ...
(Date:5/23/2017)... Mt. Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... now invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or ... dentistry services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... now welcoming new patients with periodontal plastic surgery treatments, including crown lengthening ... dentist. Dr. Green provides these esthetic and functional procedures to help patients improve ...
(Date:5/22/2017)... ... May 22, 2017 , ... “Homeostasis: The Journey of ... to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride that ... the dead of winter and to a dark place where Donald considers suicide. ...
Breaking Medicine News(10 mins):